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The identification of cancer-specific vulnerability genes is one of the most promising approaches for developing more effective and
less toxic cancer treatments. Cancer genomes exhibit thousands of changes in DNA methylation and gene expression, with the vast
majority likely to be passenger changes. We hypothesised that, through integration of genome-wide DNA methylation/expression
data, we could exploit this inherent variability to identify cancer subtype-specific vulnerability genes that would represent novel
therapeutic targets that could allow cancer-specific cell killing. We developed a bioinformatics pipeline integrating genome-wide
DNA methylation/gene expression data to identify candidate subtype-specific vulnerability partner genes for the genetic drivers of
individual genetic/molecular subtypes. Using acute lymphoblastic leukaemia as an initial model, 21 candidate subtype-specific
vulnerability genes were identified across the five common genetic subtypes, with at least one per subtype. To confirm the
approach was applicable across cancer types, we also assessed medulloblastoma, identifying 15 candidate subtype-specific
vulnerability genes across three of four established subtypes. Almost all identified genes had not previously been implicated in
these diseases. Functional analysis of seven candidate subtype-specific vulnerability genes across the two tumour types confirmed
that siRNA-mediated knockdown induced significant inhibition of proliferation/induction of apoptosis, which was specific to the
cancer subtype in which the gene was predicted to be specifically lethal. Thus, we present a novel approach that integrates
genome-wide DNA methylation/expression data to identify cancer subtype-specific vulnerability genes as novel therapeutic targets.
We demonstrate this approach is applicable to multiple cancer types and identifies true functional subtype-specific vulnerability
genes with high efficiency.
Oncogene; https://doi.org/10.1038/s41388-021-01923-1
INTRODUCTION
Cancer is widely recognised as a genetic and epigenetic disease
[1]. Large-scale changes in the genetic and epigenetic landscape
in cancer cells lead to cellular transformation [2]. Alterations in
epigenetic mechanisms, particularly alterations in DNA methyla-
tion, have been found in all cancer types. It is now clear that
inactivation due to promoter methylation is one of the primary
mechanisms leading to the loss of expression of tumour
suppressor genes, such as MLH1 and BRCA1 [3].
Genome-wide approaches have revealed the large extent of
altered DNA methylation in cancers, where several thousand
promoter-associated CpG islands become hypermethylated in a
single tumour [4]. Moreover, it has become further apparent that
methylation changes are not restricted to gene promoters and
that the overall patterns of altered DNA methylation in cancers are
highly complex [5].
DNA methylation profiling approaches have determined that
each cancer type is associated with a characteristic DNA
methylation “fingerprint” [6, 7]. Within specific tumour types,
methylation profiling can be used to identify specific subtypes,
often associated with differences in clinical behaviour and
outcomes. In childhood acute lymphoblastic leukaemia (ALL), it
has been shown that methylation profiles are strongly linked to
cytogenetic differences, such that clustering of methylation data
can recapitulate the same genetic subtypes achieved through
cytogenetic analysis [8, 9]. In multiple other types of cancer,
methylation profiling can identify biologically distinct subgroups
with distinct biological and clinical characteristics [10]. Thus,
within a specific tumour type, there are a set of methylation
changes that are shared across all/most patients, and a second set
of methylation alterations that are subtype-specific.
While classifying cancer has become easier due to the ability to
assay large numbers of CpG loci, the scale of the changes makes
it very challenging to distinguish the presumably small number
of biologically crucial changes from the very large number of
passenger events. Similarly, gene expression differences between
subtypes also typically involve very large numbers of genes [11],
making it equally challenging to identify key expression changes.
However, here we present an approach that can actively exploit
the large number of passenger changes in DNA methylation and
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gene expression and uses this to identify subtype-specific
vulnerability (SSV) partner genes for the genetic changes
underlying the development of specific genetic/molecular sub-
types of cancer. In essence, this approach, through the
integration of genomic methylation and expression data,
identifies genes that are prevented from acquiring passenger
methylation (and whose expression is retained), only in the
presence of a specific cancer-causing mutation/pathway. This
implies selection for retention of expression of the gene only in
presence of that specific cancer-driving mutation. Identification
of such SSV genes will be crucial for improving cancer therapy, as
they are ideal targets for the development of novel therapeutic
strategies, which can specifically target cancer cells and limit or
prevent normal cell toxicity [12].
Using ALL and medulloblastoma as models, we demonstrate
that our approach can identify candidate SSV genes in almost all
commonly recognised genetic/molecular subtypes of these
cancers. Furthermore, modulation of expression of candidate
SSV genes in ALL/medulloblastoma cell lines confirms that loss of
expression was specifically lethal in the predicted molecular
subtypes for all tested candidates (n= 7). This approach is likely to
be widely applicable for the identification of SSV genes across all/
many cancer types that could facilitate the development of
therapeutic approaches which can specifically target cancer cells,
while having limited or no toxicity against normal cells.
RESULTS
Most identified methylation changes are shared across all ALL
genetic subtypes, also occur in normal proliferating B-cells
and are independent of disease or transformation
An important step in the development of our approach for
identifying cancer subtype-specific SSV genes, is a clearer under-
standing of the underlying forces that drive the extensive changes
in genome-wide methylation and how this relates to disease
development. It has recently been shown in B-cell malignancies
that many hypermethylation events that were thought to be
disease-specific also occur in the latter stages of B-cell develop-
ment [13, 14]. To confirm this was similarly true in ALL subtypes,
we assessed a list of 9,348 CpG sites previously identified as
altered in all ALL genetic subtypes (compared with CD19-positive
B lymphocytes) [9]. 8760/9348 (93.7%) of the CpG sites exhibit
altered DNA methylation in the same direction seen in ALL when
terminally differentiated class-switched memory B-cells were
compared to naïve B-cells (p= 8 × 10−64, Table 1). Over 80% of
these sites exhibit beta changes of >0.1 (equivalent to an
approximately >10% change in absolute methylation) when
comparing class-switched memory B-cells to naïve B-cells. Of
these larger changes, 7371/7518 (98%) are altered in the same
direction in class-switched memory B-cells as in ALL cells (p= 2 ×
10−68, Table 1B).
This suggests that the overwhelming majority of methylation
changes seen in ALL are not disease-specific and can occur in B
lymphocytes regardless of transformation status. Crucially, this
implies that there are a large number of CpG sites that invariably
acquire altered methylation in all clones of proliferating B-cells,
whether they are transformed or not, unless there is a specific
selective pressure to prevent it. Based on this, we hypothesised
that if these “inevitable” methylation changes happened to occur
at a gene that was a SSV partner for a specific cancer-causing
mutation, then this SSV gene partner of the cancer-causing
mutation could be identified by the retention of low methylation
(and continued gene expression) only within one specific genetic/
molecular subtype. A further advantage of any such identified
genes is that, as they are highly methylated and unexpressed in all
other subtypes of that cancer, we know, a priori, that the gene
cannot be generally required for normal cell survival/proliferation.
Outline of approach for integration of genome-wide DNA
methylation and gene expression data to identify subtype-
specific SSV genes
Genome-wide DNA methylation changes in ALL can be broadly
separated into changes shared across all ALL subtypes, as
described above, and subtype-specific changes [9]. This altered
DNA methylation can be viewed as occurring in two different
processes—one that affects a very large number of loci that are
shared across all subtypes, and is likely a result of extensive
proliferation. Then the second, affecting a smaller number of loci,
modulates this pattern according to the biological differences
induced by different genetic initiating events (Fig. 1A). As
illustrated in Fig. 1A, it is this second phase in which differential
patterns of DNA methylation/gene expression might be selected
for at SSV partner genes for the specific mutation driving that
cancer. This is because, from the large number of genes affected
in the proliferation-dependent wave, any gene whose expression
is required for the growth/survival of cells bearing that specific
genetic initiating mutation will be strongly selected to retain low
methylation (if that methylation negatively impacts gene expres-
sion, see integration with gene expression data below). This will
result in low methylation in that specific genetic subtype but high
methylation in all other subtypes (example in Fig. 1B). This is in
contrast to genes required more generally for survival of
progenitor B-cells, which would exhibit low methylation in all
ALL subtypes and normal cells. Importantly, methylation acts in cis
Table 1. Comparison of methylation changes in ALL and normal B cells.
Methylation change in ALLa
Methylation change in normal CS memory B cellsb Hypermethylated Hypomethylated
Hypermethylated 8680 45
Hypomethylated 543 80
Methylation change in ALL
Methylation change (>10%) in normal CS memory B cellsc Hypermethylated Hypomethylated
Hypermethylated 7321 20
Hypomethylated 127 50
a9348 CpG sites identified by Nordlund et al.9 as exhibiting altered methylation (beta value change of >0.2) in all ALL genetic subtypes (compared with total
CD19-positive cells).
bChanges in the same direction as in ALL were observed in CS (class switched) Memory B cells (compared with naïve B cells) for 93.7% of CpG sites (p= 8 ×
10−64, Fisher Exact Test).
cAnalysis was restricted to CpG sites exhibiting large changes (beta value change of >0.1) in CS memory cells (found in 7518/9348 CpG sites (80.4%)). Sites with
such large changes were even more likely to mirror changes seen in ALL ((98% of CpG sites change in the same direction, p= 2 × 10−68, Fisher Exact Test).















and thus the selected methylation difference can only impact the
expression of the linked gene, allowing the specific target of this
selective process to be identified.
Genome-wide methylation analysis is then integrated with
genome-wide expression data, to restrict the further analysis to
loci at which the altered DNA methylation is associated with a
corresponding change in gene expression (Fig. 1). In addition to
positive expression of the candidate gene in the subtype of
interest, SSV genes should exhibit very low/absent expression in
all other subtypes and in normal haematopoietic cells. This would
E.C. Schwalbe et al.
3
Oncogene
thereby demonstrate that the gene is not required for the growth/
survival of B-cells in general (example in Fig. 1C). By combining the
methylation and expression data in our candidate selection, this
ensures that selection is occurring directly at that specific locus (as
methylation only acts in cis) and that it leads to a biological effect
(as expression of the candidate is restricted to the subtype being
studied) and that we identify only candidates that are not required
for normal B cell growth/survival (as expression is low/absent in all
other subtypes and normal cells).
Identification of SSV genes in specific genetic subtypes of ALL. As
proof of principle of the approach described above, we initially
studied the two most common ALL genetic subtypes driven by
single specific genetic events; the ETV6-RUNX1 and TCF3-PBX1
subtypes of ALL. A bioinformatic pipeline was designed to enable
this analysis (outlined in Fig. 1D). Our own [8] and publicly
available genome-wide DNA methylation analysis [9] was inte-
grated with a publicly available gene expression data set
(Leukaemia Mile Study [15]) to enable the identification of SSV
gene candidates.
We identified six candidate genes that fulfilled all criteria in
ETV6-RUNX1 and nine in TCF3-PBX1 (details listed in Table 2,
methylation and expression levels for ETV6-RUNX1 are illustrated
in Fig. 2, with differentially methylated regions (DMRs) shown in
their genomic context in supplementary Fig. 1, methylation and
expression levels for TCF3-PBX1 are illustrated in supplementary
Fig. 2). Most of the identified genes have not been studied for
their role in ALL, emphasising that this approach is likely to
generate novel potential target genes, with the exception of
IGF2BP1 (ETV6-RUNX1) and WNT16 (TCF3-PBX1). IGF2BP1, has
previously been identified as overexpressed in ETV6-RUNX1 ALL.
It is required for stability of the ETV6/RUNX1 fusion transcript [16]
and IGF2BP1 knockdown inhibits growth and survival of ETV6-
RUNX1 positive cells [17], compatible with a SSV function in ETV6-
RUNX1 positive ALL. Similarly, WNT16 has previously been
identified as overexpressed in TCF3-PBX1 positive ALL and is
required for cell survival of TCF3-PBX1 positive cells [18].
Our hypothesis further predicts that methylation patterns of the
identified SSV genes should be reflective of naive B-cells in the
subtype in which they are specifically lethal (i.e. will have retained
the methylation patterns seen in normal cells that have not
undergone extensive proliferation). In contrast, methylation
patterns in all other ALL subtypes should mirror that seen in
class-switched memory B-cells (i.e. normal cells that have under-
gone extensive proliferation). Analysis of individual CpG sites
across the six ETV6-RUNX1 candidates (Supplementary Table 1),
confirmed that the methylation patterns across these genes
match that seen in the predicted normal cell populations. This
emphasises that the methylation patterns at the identified SSV
gene candidates are reflective of normal states. The disease-
specific event is not the hypermethylation of these genes, but the
retention of the non-proliferative/naive cell pattern in the genetic
subtype in which the gene was identified as a SSV candidate.
We selected one candidate from each genetic subtype (TUSC3
for ETV6-RUNX1 and FAT1 for TCF3-PBX1) for function assessment.
For TUSC3, this analysis utilised the ETV6-RUNX1 positive REH cell
line (which expresses TUSC3, as predicted for ETV6-RUNX1 positive
ALL cells) and the ETV6-RUNX1 negative NALM6 cell line (in which
TUSC3 is hypermethylated and inactivated, as predicted for ETV6-
RUNX1 negative ALL cells) (Fig. 3A). As TUSC3 has also previously
been suggested as a potential tumour suppressor gene, in part
due to its frequent hypermethylation [19], we also assessed any
negative impact on the growth of re-expression of the gene in the
TUSC3-deficient NALM6 cell line. In REH cells, expression of TUSC3
was reduced (65–75%) by treating with either of two different
siRNA constructs targeted against TUSC3 (Fig. 3A). Although
knockdown was only partial, this had a significant impact on cell
growth, resulting in 40–60% reduction in cell numbers 4 days post
treatment (Fig. 3C). Furthermore, knockdown of TUSC3 resulted in
induction of apoptosis specifically in the ETV6-RUNX1 positive REH
cells (Fig. 3D). As expected, treatment of TUSC3 negative NALM6
cells with TUSC3 siRNA had no impact on cell growth or apoptosis
(Fig. 3C, D). Furthermore, re-expression of TUSC3 in NALM6 cells, at
levels equivalent to the endogenous expression in REH (Fig. 3A),
had no detectable impact on the growth of the NALM6 cells
(Fig. 3B), indicating that these cells are insensitive to modulation
of TUSC3 expression level.
Similarly, FAT1 function was assessed in TCF3-PBX1 positive ALL
cell lines (PreB697 and MHH CALL3), which express FAT1 and
exhibit low FAT1 methylation (as seen in TCF3-PBX1 primary
samples), as well as a control TCF3-PBX1-negative line REH, in
which the FAT1 gene is hypermethylated and not expressed. As
seen for TUSC3 in the ETV6-RUNX1 subtype, partial siRNA-mediated
knockdown of FAT1 resulted in inhibition of cell growth and
induction of apoptosis in cell lines from the relevant subtype (i.e.
PreB697 and MHH CALL3). In contrast, it had no impact on cells
Fig. 1 Outline of the process that leads to the proposed generation of SSV genes in ALL. A Step 1—Co-ordinated methylation of thousands
of promoter-associated CpG islands—seen in essentially all ALL cases. This will result in a mixed population of cells some with (red cells) and
some without (green cells) inactivation of specific SSV genes. Step 2—Initiating genetic lesion drives clonal expansion of epigenetically
disrupted cells. Step 3—The result is a natural “experiment” in which all genes affected at step 1 are “tested” for subtype-specific lethality. i.e.
cells in which a SSV gene for the specific genetic initiating mutation is methylated and inactivated will be lost during clonal expansion (red
cells), while cells with no SSV genes methylated/inactivated will clonally expand. Subsequently we can identify SSV genes based on their
unusual methylation patterns (i.e. high methylation in all other subtypes, but very low methylation in the specific genetic subtype for which
the gene is specifically lethal). For illustrative purposes genome-wide and subtype-specific methylation changes (driven by the initiating
genetic event) are shown as occurring sequentially. They may occur simultaneously, during the initial stages of clonal expansion driven by the
subtype-specific defining mutation, but this would not alter the hypothesis as hypermethylation of SSV genes would still be selected against
only in the genetic subtype in which they are specifically lethal. B Illustrative example of the methylation differences identified between
genetic subtypes for potential SSV genes. These illustrative examples show the methylation difference between ETV6-RUNX1 ALL and all other
subtypes at a DMR overlapping the DSC3 promoter region. This is typical of the predicted pattern of methylation for SSV genes derived as
described in (A). C Integration with gene expression data. Only genes where the altered DNA methylation is associated with the predicted
subtype-specific gene expression are retained as candidate SSV genes. In this example, the candidate gene (DSC3) exhibits high expression in
the subtype of interest (B-ALL ETV6-RUNX1) but low/absent expression in all other subtypes, thus demonstrating that it is not generally
required for cell growth/survival for B-cells. This suggests that targeting such a gene should specifically affect the cancer cells with the
particular cancer-initiating mutation. D Flow diagram of the bioinformatics pipeline for identification of SSV gene candidates. (1) All DMRs for
a specific subtype of cancer under study are initially selected using DMRcate. (2) The initial region is then further analysed to identify the
maximally divergent region (must contain at least 2 CpG sites). (3) This region is then tested in comparison with all other subtypes of cancer
under study and only regions that are divergent from every other subtypes are retained as markers of potential SSV genes. (4) Gene
expression data sets are used to analyse the expression of the nearest gene from loci derived from step 3, to identify those in which the
reduced methylation is associated with subtype-specific gene expression. Genes in which expression is exclusive to the subtype of interest
are taken forward as SSV candidates.
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from a different genetic subtype (i.e. Reh) (Fig. 4). Thus, for both
genes, retention of expression was required for cell growth and
survival, exclusively in cells bearing the cancer-causing mutation
that the genes were predicted to be specifically lethal with.
Identification of SSV candidates in other ALL subtypes. To
investigate the wider applicability of this approach, we
expanded this initial analysis to other ALL subtypes, including
those with less specific genetic changes (e.g. high hyperdi-
ploidy). Using our approach, SSV gene candidates were identified
in all genetic subgroups in ALL (Table 2; DNA methylation and
gene expression data for all identified candidates is detailed in
supplementary Fig. 2). As for the above analysis, most identified
genes have not been widely studied for their role in leukaemia
and represent potentially novel therapeutic targets. Thus the
approach described here can be used to identify SSV gene
candidates across subtypes defined by a wide range of known
and less defined molecular abnormalities.
Identification of SSV gene candidates in medulloblastoma. After
proof of principle across ALL subtypes, we next investigated
whether SSV gene candidates could be identified in a non-
haematological cancer, medulloblastoma. This CNS tumour
comprises four molecularly defined subgroups (WNT, SHH, Group
3 and Group 4), defined through international consensus and
which are identifiable by transcriptomic or methylomic signatures
[20, 21]. Using our novel approach, SSV gene candidates were
identified in WNT, SHH and Group 4 subgroups (Table 3, DNA
methylation and gene expression data for all identified candidates
is detailed in supplementary Fig. 3). Again, identified genes
represent potentially novel therapeutic targets. Furthermore, the
medulloblastoma dataset included both adult and childhood
patients and the identification of SSV gene candidates was found
to be dependent on the molecular subgroup but independent of
patient age (Supplementary Fig. 3). These results suggest that the
reported approach could have broad applicability across different
cancer types.
Table 2. Candidate SSV genes identified in ALL genetic subtypes.
ETV6-RUNX1
Gene symbol EntrezID Chr Distance to TSS DMR_Starta DMR_End Size of DMR
DSC3 1825 chr18 0 28620915 28624074 3159
DSC2 1824 chr18 0 28681121 28683794 2673
IGF2BP1 10642 chr17 15177 47089952 47092272 2320
NOVA1 4857 chr14 0 27065974 27069329 3355
PTPRK 5796 chr6 0 128839906 1.29E+ 08 2499
TUSC3 7991 chr8 0 15397211 15398333 1122
TCF3-PBX1
Gene symbol EntrezID Chr Distance to TSS DMR_Start DMR_End Size of DMR
CHST6 4166 chr16 0 75528459 75529892 1433
DCHS2 54798 chr4 0 155410477 155413789 3312
FAT1 2195 chr4 0 187644620 187648358 3738
NLGN1 22871 chr3 0 173113110 173116248 3138
PHACTR3 116154 chr20 0 58151913 58152803 890
SPAG6 9576 chr10 0 22633916 22635028 1112
TCERG1L 256536 chr10 0 133109013 133111331 2318
UGT8 7368 chr4 0 115518992 115521241 2249
WNT16 51384 chr7 0 120967900 120970606 2706
High hyperdiploidy
Gene symbol EntrezID Chr Distance to TSS DMR_Start DMR_End Size of DMR
CADPS 8618 chr3 0 62859289 62861925 2636
PLVAP 83483 chr19 0 17487776 17489311 1535
MLL/11q23
Gene symbol EntrezID Chr Distance to TSS DMR_Start DMR_End Size of DMR
SKIDA1 387640 chr10 1446 21802824 21805402 2578
ZC3H12C 85463 chr11 0 109962727 109964976 2249
BCR/ABL1
Gene symbol EntrezID Chr Distance to TSS DMR_Start DMR_End Size of DMR
MIRLET7BHG 400931 chr22 4750 46468422 46471442 3020
PDK4 5166 chr7 0 95225520 95226433 913
aBased on the GRCh37 genome assembly.
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Functional assessment of SSV gene candidates in
medulloblastoma
Most of the identified SSV gene candidates were in the WNT and
SHH subtypes. However, as cell line models are not available for
WNT medulloblastoma, we focused on functional validation of the
SHH candidates. siRNA were obtained for five of the SHH
candidate SSV candidates and used to transfect two SHH
medulloblastoma cell lines (UW228 and DAOY). Knockdown of
each of the five candidate genes induced a significant reduction in
cell numbers in the SHH medulloblastoma cell lines, demonstrat-
ing that targeting these genes was able to induce anti-
proliferative effects in SHH medulloblastoma cells as predicted
(Fig. 5A). The relative impact of targeting the genes was variable.
Knockdown of the PNPLA2 gene only resulted in a minor reduction
of about 20% (which was only statistically significant in one of the
two cell lines), while knockdown of the majority of the candidates
resulted in larger decreases of 40–60% relative to the non-
silencing control (Fig. 5A). Furthermore, we examined caspase
activation, as a measure of apoptosis. Again, knockdown of all five
candidate genes resulted in significant induction of caspase
activity, implying that knockdown of the candidate genes was at
least in part cytotoxic (Fig. 5B). Assessment of the efficiency of
knockdown at the RNA level by qRT-PCR identified reduced
expression of the targeted genes 48 h post siRNA transfection
(supplementary Fig. 4). Protein expression was also assessed for
three of the targets (ATOH1, CRIP2 and PNPLA2), demonstrating
protein levels were also reduced at 48 h post-transfection
(supplementary Fig. 4B). Thus, all five tested genes exhibited
functional activity consistent with subtype-specific lethality,
suggesting that the approach identifies functional SSV genes
with a high degree of efficiency.
DISCUSSION
The large extent and complexity of molecular changes occurring in
cancer makes the identification of key changes very challenging.
Here we present a novel approach, integrating genome-wide DNA
methylation and expression data, that can actually utilise the very
large number of passenger changes to allow identification of
candidate SSV genes. We demonstrate this approach can identify
SSV gene candidates in almost all molecular subtypes assessed and
functional analysis validated all candidate genes tested. siRNA-
mediated knockdown of all seven of the tested candidates resulted
in reduced cell growth and the induction of apoptosis, suggesting
that the approach we report here identifies SSV genes with a high
degree of efficiency. We further demonstrated that SSV genes
could be identified in both adult and childhood medulloblastoma.
As similar extensive DNA methylation changes occur in all tumour
types it is likely that this approach will be applicable to many other
cancers. This could allow the identification of novel therapeutic
targets for the development of therapies with the potential to
specifically target cancer cells, while achieving minimal normal cell
toxicity. This would be crucial in improving cancer outcomes,
enabling treatment in less robust patient groups, such as the
elderly, and in reducing the long-term health effects suffered by
survivors of childhood/young adult cancer.
This study focussed on the identification of SSV genes that are
required in specific molecular subtypes of cancer. While most
cancers were initially classified based on morphology, detailed
molecular analysis has suggested the different molecular subtypes
are quite distinct, displaying differences in patient outcome [22],
gene expression profiles [23] and genome-wide methylation [9].
Consequently, each molecular subtype is likely to exhibit its own
specific SSV genes and co-operating mutations. Consistent with
the existence of molecular subtype-specific lethal genes, we found
unique candidates in almost all molecular subtypes analysed in
ALL and medulloblastoma. However, it is also possible that SSV
Fig. 2 Methylation and gene expression patterns of all SSV genes
identified in the ETV6/RUNX1 subtype. Gene expression plots in B-
cell ALL genetic subtypes (derived from BloodSpot, http://servers.
binf.ku.dk/bloodspot/) and DNA methylation data from the region of
largest change within each DMR are shown for all six candidate SSV
genes identified in the ETV6-RUNX1 subtype.
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genes may be shared across some or all different genetic subtypes
and modifications of our current approach will be utilised to
assess this in subsequent studies.
A key to our approach for identifying such subtype-specific lethal
genes, lies in the unique features of abnormal methylation present
in all cancer types. The comparatively high error rate in replicating
methylation patterns results in the accumulation of high levels of
aberrant promoter-associated methylation, which is incompatible
with expression of the linked gene. As many genes are either not
expressed or not required for growth/survival in specific cell types,
the genes impacted by such aberrant methylation in a specific cell
type are quite consistent and therefore predictable. However, as
illustrated in Fig. 1, if a gene is a SSV gene in one specific molecular
subtype, there will be a very strong selective pressure, only in this
subtype, to maintain low methylation that is compatible with
retained expression. Thus, genes required for survival specifically in
one molecular subtype can be identified by a specific failure to
accumulate methylation, which does accumulate in all other
subtypes where the gene is not required. Importantly, methylation
changes function in cis and thus alterations at a specific promoter
will only affect the linked gene. Thus, the gene targeted by the
differential methylation can readily be identified. Consistent with
this hypothesis, all seven genes functionally assessed in this study
exhibited subtype-specific lethal properties, suggesting that the
approach we describe can identify functional SSV genes with a
high degree of specificity.
Three genes identified by this approach in ALL and medullo-
blastoma have already been implicated with activity consistent
Fig. 3 TUSC3 expression is required for the growth and survival of ETV6-RUNX1 expressing cells. A TUSC3 expression as determined by
qRT-PCR in Reh cells with and without treatment with siRNA directed against TUSC3 and also in NALM6 cells before and after transduction
with a TUSC3 expression construct. B TUSC3 expression has no significant impact on NALM6 cells. NALM6 cells were transduced with an empty
vector, expressing GFP alone (EV) or a TUSC3 expression vector, also expressing GFP (TUSC3). The retention of GFP-expressing cells was
followed in a mixed population. As expected expression of GFP alone had no impact on growth survival, as illustrated by the fraction of GFP-
expressing cells remaining essentially constant over 21 days. Similarly, TUSC3 expressing cells also remained constant over the assessment
period, indicating that modulation of TUSC3 expression had no significant impact on the growth of ETV6-RUNX1 negative NALM6 cells.
C Knockdown of TUSC3 in Reh cells significantly reduces cell growth. Knockdown of TUSC3 with two different siRNA constructs resulted in a
65–75% reduction in expression (see (A)). Cell growth by 4 days following knockdown with either construct was very significantly reduced, as
compared with control non-silencing RNA (NS-siRNA). *p < 0.01. D Knockdown of TUSC3 induces apoptosis in Reh cells. Forty-eight-hours post
transfection, apoptosis was assessed in Reh cells exposed to TUSC3 specific siRNA versus control non-silencing siRNA. While treatment with the
control siRNA resulted only in a very low level of apoptosis, levels of apoptosis were significantly higher following treatment with TUSC3
specific siRNA (p < 0.01). Overall these results show that modulation of TUSC3 expression levels specifically inhibits cell growth/survival in
ETV6-RUNX1 positive cells.
E.C. Schwalbe et al.
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with subtype-specific lethality. However, the majority of candi-
dates identified have not previously been implicated in leukae-
mia/medulloblastoma biology. This includes six of the seven
genes in which SSV gene activity was functionally confirmed. Key
to this identification of previously unappreciated genes, is that the
approach relies on the identification of genes that are not
genetically disrupted and whose methylation patterns initially
appear to reflect that seen in normal cells and thus would not
be identified by standard epigenetic/genetic screening. Thus, the
approach reported here could allow the identification of a large
number of previously unidentified therapeutic targets across a
wide range of cancers.
Whilst previous analysis of genetic/epigenetic changes would
not have readily identified the genes identified here, some could
have been identified solely through subtype-specific overexpres-
sion (as was the case for IGF2BP1 [16, 17] and WNT16 [18] in ALL
and ATOH1 [24] in medulloblastoma). However, the number of
expression differences between subtypes is typically very high.
Ross et al. [11] identified close to one thousand discriminating
differences in expression in multiple ALL genetic subtypes. This is
likely because altered expression of a specific gene usually reflects
alterations to upstream regulators, such as transcription factors or
signalling pathways. These act in trans and can alter the
expression, directly and indirectly, at very large numbers of genes.
Therefore, gene expression patterns alone cannot readily be used
to identify changes that are of key functional importance. This is in
contrast to DNA methylation changes, which, as discussed above,
act in cis. Consequently, the inclusion of DNA methylation data
greatly enhances the ability of our approach to identify genes
under direct selection, as opposed to secondary passenger
changes. The high “hit-rate” we obtained in the seven tested
candidate SSV genes implies that this is a highly efficient method
for identifying true functional SSV genes.
The majority of ALL patients have one of a number of well-
defined genetic abnormalities and these abnormalities are
thought to be critical initiating events for the disease [25]. Whilst
the number of candidate SSV genes identified varied (from 2 to 9
candidates), potential SSV genes were identified for all genetic
subtypes assessed. This implies that the approach we are using
can identify candidate SSV genes across a broad range of different
genetic initiating events. It may be that the approach will be most
successful for subtypes with clearly defined molecular changes
(i.e. ETV6/RUNX1, TCF3-PBX1, BCR-ABL1) as opposed to subtypes
with more heterogeneous changes (i.e. HeH, MLL/11q23), as a
Fig. 4 Knockdown of FAT1 specifically alters the growth/survival of TFC3-PBX1 cells. FAT1 exhibits TCF3-PBX1 specific patterns of (A)
Methylation and (B) expression, compatible with TCF3-PBX1 subtype-specific lethality. C Treatment of two different TCF3-PBX1 positive cell
lines (PreB 697 and MHH cALL3) with a siRNA against FAT1 results in an ~60% reduction in FAT1 expression 48-hours post transfection, as
assessed by qRT-PCR. D Cell growth following knockdown with FAT1 specific siRNA is dramatically reduced compared with non-silencing
siRNA in both TCF3-PBX1 positive cell lines (p < 0.002 for both). In contrast no impact is seen in the TCF3-PBX1/FAT1-negative cell line Reh,
indicating that this is not due to an off-target effect. E Treatment with FAT1 siRNA results in a small but statistically significant increase in
apoptosis in TCF3-PBX1 positive cell lines, as compared to control non-silencing siRNA (p < 0.05 for both). As expected, FAT1 siRNA has no
significant impact on apoptosis levels in FAT1-negative Reh cells.
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greater number of candidate SSV genes were found for the former
group than the latter. Similarly, in medulloblastoma, analysis of
the well-defined WNT and SHH subgroups identified seven
candidate SSV genes in each. In contrast, identification of SSV
genes was limited in group 3/group 4 tumours, which lack a
known subgroup-defining molecular defect and show evidence
for overlapping biology [10, 26].
Several other techniques have been reported for identifying
synthetic lethal or SSV genes, including approaches that utilise
siRNA, shRNA and CRISPR libraries [27, 28] and bioinformatic
approaches [29–31]. This has led to the development of an
extensive database of potential synthetic lethal interactions [32].
Each technique has different advantages and disadvantages and
use of complementary approaches may be optimal for the
identification of lethal genes relevant for all cancer subtypes.
The approach we describe here has a number of advantages over
previously developed methods. Firstly, it focuses on specific
molecular subtypes and only identifies genes that are expected to
be functionally relevant in most/all cases of that particular
subtype. This is unlike methods based on identifying partners
for specific mutations, which may only be present in a subset of
cases and for which different mutations of the same gene could
have different lethal partner genes. Unlike the experimental
screening approaches, which are often carried out in model
systems, our approach identifies selective events occurring in vivo
in patients and thus the identified targets will not be model
dependent. A limitation of our approach is that it is only able to
identify SSV genes that are susceptible to methylation during
tumour development and thus won’t detect all potential SSV
genes. Consistent with this, we failed to detect SSV gene
candidates in one of the nine molecular subtypes analysed in
ALL and medulloblastoma, although candidates were identified in
the other eight subtypes. Importantly, our approach has a high
signal-to-noise ratio, demonstrated by the high hit-rate for
validation of SSV genes in the functional studies. While the
sensitivity of our approach may be lower than some previously
reported methods, the results suggest that the specificity of
identification of candidate SSV genes is high. Coupled with the
comparative technical simplicity and low costs of the method, we
believe that our approach has the potential to significantly
enhance the detection of in vivo relevant cancer= -specific
lethal genes.
Overall, the approach presented here represents a promising
new approach to uncover previously unidentified SSV genes
which could represent highly promising targets for the develop-




For ALL, we used methylation array datasets (GSE49031, GSE69229) [8, 9].
For medulloblastoma, DNA methylation/gene expression for 763 primary
medulloblastoma samples was obtained from GSE85218 [33]. All
medulloblastoma samples had previously been placed in one of the four
consensus medulloblastoma subgroups (WNT, SHH, Group 3 or Group 4)
Table 3. Candidate SSV genes identified in medulloblastoma subtypes.
WNT
Gene symbol EntrezID Chr Distance to TSS DMR_Starta DMR_End Size of DMR
LINC01124 440925 chr2 0 171568412 171574592 6180
LRP4 4038 chr11 0 46939436 46941490 2054
MIR193A 406968 chr17 0 29885787 29888936 3149
NKD1 85407 chr16 0 50580632 50585731 5099
PHETA2 150368 chr22 0 42469756 42470868 1112
RASIP1 54922 chr19 0 49242037 49244965 2928
SYK 6850 chr9 0 93563776 93564603 827
SHH
Gene symbol EntrezID Chr Distance to TSS DMR_Start DMR_End Size of DMR
ATOH1 474 chr4 5441 94755520 94756895 1375
CPLX1 10815 chr4 7060 811641 812884 1243
CRIP2 1397 chr14 5328 105944604 105946891 2287
FOXS1 2307 chr20 0 30431758 30434529 2771
GPR68 8111 chr14 18919 91699881 91701304 1423
PNPLA2 57104 chr11 3495 822397 824970 2573
SPHK1 8877 chr17 8471 74381214 74383906 2692
Group 3
Gene symbol EntrezID Chr Distance to TSS DMR_Start DMR_End Size of DMR
None identified
Group 4
Gene symbol EntrezID Chr Distance to TSS DMR_Start DMR_End Size of DMR
LMX1A 4009 chr1 0 165321224 165327830 6606
aBased on the GRCh37 genome assembly.
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based on integrated analysis of gene expression and genome-wide DNA
methylation data [33]. Methylation data were processed as previously
described [8]. In total, we used data from 509 samples from seven different
leukaemia subtypes (Supplementary Table 2). Analysis of gene expression
in ALL was performed using microarray data available from the MILE study
(GSE13204; n= 637 samples) [15].
Bioinformatic and statistical analysis
Bioinformatic analyses were undertaken using R v3.4.0 (https://www.r-
project.org/foundation). To identify candidate SSV genes, we undertook
pairwise comparisons of cancer subtypes. We first identified DMR
candidates using DMRcate [34]. DMRs were selected on the basis of
average beta-value difference across the full DMR exceeding 0.2. This initial
pass was performed by comparing the subtype of interest to all other
subtypes combined. From these DMRs, we selected regions for further
analysis if the maximum beta-value change at a single locus within the
DMR exceeded 0.35 and if the DMR was located within/overlapped a CpG
island. For this analysis, the subtype of interest was compared to all other
subtypes in pairwise comparisons to ensure that differential methylation
was specific for only that subtype. Regions returned by DMRcate are
typically variable and contain regions of minimal methylation change as
well as regions of large methylation differences. In order to identify the
maximally changed regions, we initially selected a minimum of two
adjacent CpG loci whose average absolute difference between groups was
the greatest. Next, we sought to expand this region by iteratively moving
up/downstream of the selected CpGs. We balanced expanding the
maximally changed region and maintaining a large absolute methylation
change, by incorporating adjacent CpGs into the maximally changed
region if the combined average was greater than/equal to the original CpG
locus pair difference. We removed DMRs located further than 20 kb from
the transcriptional start site of a gene. Using transcriptome microarray
data, we identified subtype-specific differentially expressed genes using
limma and assessed the expression of candidate SSV genes identified from
the DNA methylation screen.
Statistical assessments of differences in cell growth and apoptosis were
carried out using the student t-test, assuming equal variances, with
p-values < 0.05 deemed statistically significant.
CODE AVAILABILITY
Code for identification of SSV genes is available on GitHub.
Additional methods in online supplementary material.
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